Wednesday, April 27, 2022 Daily Archives

Novartis CGTs first quarter 2022: Zolgensma up, Kymriah down

by

Novartis reports increased sales for gene therapy Zolgensma due to expanded global access, but the failure in the second-line DLBCL setting will affect Kymriah sales. For Swiss Pharma giant Novartis’ cell and gene therapy (CGT) division, first quarter 2022 results were mixed. On the positive side, Zolgensma (onasemnogene abeparvovec) pulled in $363 million during the quarter, up 18% year-on-year due to increased access outside of the US. Sales of the one-time spinal muscular atrophy (SMA) gene therapy — approved in the…

April 27, 2022

Formulation lap: Sanofi turns to McLaren for manufacturing efficiency

by

Sanofi has teamed with Formula 1 racing team McLaren to optimise manufacturing efficiencies within its network. The multiyear deal will see Sanofi’s Industrial Affairs team benefit from McLaren Racing team’s digital and analytical expertise tto achieve excellence in manufacturing operations. “Analysis of losses, modelling and simulation of production line scheduling, and specifically product change-overs, will be key areas to maximise performance in Sanofi manufacturing sites,†McLaren said in a press release. Both Sanofi and McLaren Racing “operate in a truly…

April 27, 2022

NorthX Biologics inks vaccine partnership with Abera

by

NorthX has signed a partnership agreement to upscale and manufacture Abera Biosciences’ vaccine candidate against pneumococcus, Ab-01.12.   Abera is a vaccine and platform development company, which was founded in 2012 as a spinout from Swedish production firm Xbrane Bioscience. Its lead vaccine candidate Ab-01.12 is administered as a nasal spray and aims to treat pneumococcus using technology designed to protect against all variants of the bacterium. Abera is preparing the vaccine candidate for clinical trials in humans and has…

April 27, 2022